Answers are grounded in this paper and cite their sources.
Investigates oHSV-1's effect on glioblastoma cells, suggesting promising therapeutic approaches.
Oncolytic virus therapy is a highly promising approach for the treatment of glioblastoma (GBM). The RNA alteration N6-methyladenosine (m 6 A) is essential in GBM progression; however its specific function in oncolytic virotherapy remains unclear. We employed a new oncolytic herpes simplex virus type 1 (HSV-1), designated oHSV-1, which we had previously engineered. Mechanistic studies were performed to elucidate the involved pathways. We demonstrate that oHSV-1 specifically downregulates the m 6 A demethylase ALKBH5, leading to GBM cell death. Mechanistically, ALKBH5 downregulation elevates m 6 A modification on the transcript of the arginine methyltransferase CARM1, which promotes mRNA degradation and reduces protein expression. As CARM1 is a vital regulator of apoptosis, its loss triggers tumor cell apoptosis. Thus, our study identifies the ALKBH5–m 6 A–CARM1 axis as a critical mechanism underlying oHSV-1-induced apoptosis in GBM cells. Moreover, the combination of oHSV-1 and CARM1 inhibitor shows a markedly enhanced effect on suppressing tumor cell proliferation in vitro. These findings reveal a novel epigenetic mechanism of oHSV-1-induced apoptosis and support the therapeutic potential of combining oHSV-1 with epigenetic inhibitors for GBM treatment.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: